Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Jeremy Jones had no financial relationships to ineligible companies to disclose.View Jeremy Jones's current disclosures
Hepatic encephalopathy, also known as acute hyperammonemic encephalopathy or portosystemic encephalopathy, refers to a spectrum of neuropsychiatric abnormalities occurring in patients with liver dysfunction and portal hypertension. It results from exposure of the brain to excessive amounts of ammonia.
On this page:
Hepatic encephalopathy specifically refers to an encephalopathy occurring in patients with acute liver failure, a portosystemic shunt, or chronic liver disease. It is generally regarded as a reversible condition, although the long-term sequelae are being further studied 11.
Hepatic encephalopathy may be subclassified according to severity and pattern (acute episode, recurrent, or persistent) 11.
Chronic neurological damage ascribed to repeated episodes of hepatic encephalopathy is usually termed acquired hepatocerebral degeneration, which is discussed separately.
For the purposes of this article, we use the terms separately and discussion here is limited to acute hepatic encephalopathy.
The vast majority of patients have portosystemic shunts in the setting of cirrhosis, either from the development of spontaneous shunting or as a result of transjugular intrahepatic portosystemic shunting (TIPS) 7. The clinical spectrum can rarely manifest in individuals who have portosystemic bypass without any associated intrinsic hepatocellular disease. The broader term "portosystemic encephalopathy" can be used for this reason.
The clinical manifestations of hepatic encephalopathy range widely from chronic episodic subclinical neurological dysfunction to acute fulminant neurological impairment, coma and death 4.
The latest consensus guidelines published in 201413 from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) states that hepatic encephalopathy can be classified according to:
- the underlying cause (type A, type B, type C)
- the severity of its manifestations (using either the West Haven Criteria or the ISHEN classification, which differentiates unimpaired hepatic encephalopathy, covert hepatic encephalopathy and overt hepatic encephalopathy)
- the chronology (episodic, recurrent, persistent)
- the existence of precipitating factors (non-precipitated, precipitated)
In its lowest expression, hepatic encephalopathy can only cause memory leaks and visuospatial ability alterations. However, as it progresses, behavioral alterations and agitation appear, leading to obtundation and coma in later stages. A classically described manifestation of hepatic encephalopathy is asterixis or flapping tremor, which appears in intermediate phases. Its presence indicates an overt hepatic encephalopathy14.
In the majority of patients, a superimposed precipitating cause rather than worsening of hepatocellular function can be identified (particularly in acute situations). Such precipitants include:
- infection (most common): 50% 4
- excessive nitrogen-containing intestinal load
- gastrointestinal bleed (e.g. from varices)
- dietary intake of large quantities of protein (e.g. meat)
- reduced nitrogen excretion
- renal failure
- metabolic or drug interactions
- hyponatremia or hypokalemia (e.g. from diuretics)
The most commonly used and accepted clinical grading system for hepatic encephalopathy is the West Haven criteria 12, based on level of consciousness as well as cognitive and behavioral assessment:
- grade 0: no alteration in consciousness, intellectual function, personality or behavior
- grade 1: trivial lack of awareness, euphoria or anxiety, shortened attention span, impairment of addition or subtraction
- grade 2: lethargy or apathy, mild personality change, disorientation to time or place, inappropriate behavior
- grade 3: somnolence to semi-stupor but responsive to verbal stimuli, confusion, gross disorientation
- grade 4: coma, no response to verbal or noxious stimuli
In hepatic encephalopathy, due to portosystemic shunting, ammonia from the digestive system or from elsewhere, which is usually metabolized by the liver reaches the systemic circulation. Although the exact mechanism of neurotoxicity has not been elucidated, ammonia is taken up by the brain and has been shown to be toxic to both astrocytes and neurons 4.
MR imaging features of acute hyperammonemia include:
- symmetric high signal within the insula (most common), thalamus, and posterior limbs of the internal capsule, and cingulate gyrus 5-7
- often reversible with therapy 5,6
- diffuse cortical edema and hyperintensity
- perirolandic and occipital regions are typically spared
- similar distribution to T2/FLAIR
- reverse with appropriate therapy
- nearly one-half have microhemorrhages of white matter or cortex 8
- number and presence of microhemorrhages do not affect the outcome
- nearly one-half have microhemorrhages of white matter or cortex 8
- may show an elevated glutamine/glutamate peak coupled with decreased myoinositol and choline signals on proton MR spectroscopy 1,7
As the vast majority of cases of acute hepatic encephalopathy will be encountered in patients with established and chronic liver disease, chronic findings of acquired hepatocerebral degeneration are also usually present.
Treatment and prognosis
Acute hepatic encephalopathy can be rapidly fatal, while chronic hepatic encephalopathy tends to be a more indolent process. Identifying and treating precipitating cause is important, and leads to resolution in up to 80% of patients 4.
Treatment usually entails the careful cessation of any offending agents (e.g. toxins, chemotherapeutic agents, antiepileptic agents), treating contributing conditions (e.g. sepsis, GI bleeding), nutritional support (including the use of lactulose), and in some cases hemofiltration to remove excess ammonia.
Notably, the extent of severity on FLAIR and DWI correlates with the plasma ammonia level 5. More severe cases of diffuse cortical involvement (particularly on DWI) can be reversible but are more likely to be fatal, indicating the need for prompt therapy to treat the hyperammonemia in acute hepatic encephalopathy 5.
The differential diagnosis includes other causes of hyperammonemic encephalopathy 6,10
- 1. Rovira A, Alonso J, Córdoba J. MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol. 2008;29 (9): 1612-21. doi:10.3174/ajnr.A1139 - Pubmed citation
- 2. Naegele T, Grodd W, Viebahn R et-al. MR imaging and (1)H spectroscopy of brain metabolites in hepatic encephalopathy: time-course of renormalization after liver transplantation. Radiology. 2000;216 (3): 683-91. Radiology (citation) - Pubmed citation
- 3. Sharma P, Eesa M, Scott JN. Toxic and acquired metabolic encephalopathies: MRI appearance. AJR Am J Roentgenol. 2009;193 (3): 879-86. doi:10.2214/AJR.08.2257 - Pubmed citation
- 4. Bleibel W, Al-Osaimi AM. Hepatic encephalopathy. Saudi J Gastroenterol. 2012;18 (5): 301-9. doi:10.4103/1319-3767.101123 - Free text at pubmed - Pubmed citation
- 5. McKinney AM, Lohman BD, Sarikaya B et-al. Acute hepatic encephalopathy: diffusion-weighted and fluid-attenuated inversion recovery findings, and correlation with plasma ammonia level and clinical outcome. AJNR Am J Neuroradiol. 2010;31 (8): 1471-9. doi:10.3174/ajnr.A2112 - Pubmed citation
- 6. U-King-Im JM, Yu E, Bartlett E, Soobrah R, Kucharczyk W. Acute hyperammonemic encephalopathy in adults: imaging findings. (2011) AJNR. American journal of neuroradiology. 32 (2): 413-8. doi:10.3174/ajnr.A2290 - Pubmed
- 7. Hegde AN, Mohan S, Lath N et-al. Differential diagnosis for bilateral abnormalities of the basal ganglia and thalamus. Radiographics. 2011;31 (1): 5-30. Radiographics (full text) - doi:10.1148/rg.311105041 - Pubmed citation
- 8. Benson JC, Payabvash S, Thalken GL, Alonso J, Rykken J, Ott F, McKinney AM. Delineation of microhemorrhage in acute hepatic encephalopathy using susceptibility-weighted imaging. European journal of radiology. 85 (3): 629-34. doi:10.1016/j.ejrad.2015.12.025 - Pubmed
- 9. Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Therapeutics and clinical risk management. 5 (3): 617-26. Pubmed
- 10. Takanashi J, Barkovich AJ, Cheng SF, Kostiner D, Baker JC, Packman S. Brain MR imaging in acute hyperammonemic encephalopathy arising from late-onset ornithine transcarbamylase deficiency. (2003) AJNR. American journal of neuroradiology. 24 (3): 390-3. Pubmed
- 11. Frederick RT. Current concepts in the pathophysiology and management of hepatic encephalopathy. (2011) Gastroenterology & hepatology. 7 (4): 222-33. Pubmed
- 12. Córdoba J. New assessment of hepatic encephalopathy. (2011) Journal of hepatology. 54 (5): 1030-40. doi:10.1016/j.jhep.2010.11.015 - Pubmed
- 13. Vilstrup H, Vilstrup AP, Vilstrup BJ, Vilstrup CJ, Vilstrup FP, Vilstrup MK, Vilstrup WK, Vilstrup WP, Vilstrup. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. (2014) Hepatology (Baltimore, Md.). doi:10.1002/hep.27210 - Pubmed
- 14. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. (2011) Alimentary pharmacology & therapeutics. 33 (7): 739-47. doi:10.1111/j.1365-2036.2011.04590.x - Pubmed